San Francisco-based iRhythm Technologies closed its acquisition of San Jose's VitalConnect on Monday, paying $237.5 million in cash plus up to 423,334 shares of stock, for a total deal value of roughly $287.5 million. The combination pairs iRhythm's widely used Zio ambulatory ECG patches with VitalConnect's multi-parameter wearable biosensors, stitching together two distinct corners of the Bay Area's cardiac monitoring industry into a single company.
The cash-and-stock structure was detailed in a GlobeNewswire release confirming the deal closed October 5, with the stock component valued at about $50 million when the acquisition was first announced in August. iRhythm also supplied VitalConnect with $10 million in interim working capital between the signing and the closing, according to the same release. Digital Health News described the purchase as a move meant to strengthen iRhythm's cardiac monitoring capabilities and expand its market presence.
Quentin Blackford, iRhythm's chief executive and president, said VitalConnect's capabilities are highly complementary to iRhythm's own, broadening the company's cardiac monitoring reach. VitalConnect chief executive Peter Van Haur said joining iRhythm can extend the reach and impact of VitalConnect's technology, with the companies expecting to combine VitalConnect's sensor technology with iRhythm's scale, clinical expertise, and customer reach to accelerate platform growth.
A Decade-Old San Jose Startup Finds a Buyer
VitalConnect was based in San Jose, according to Forge Global. The company built its business around wearable biosensors designed for both in-hospital continuous monitoring and home healthcare settings. Heading into the deal, VitalConnect was operating at an annual revenue run rate of approximately $65 million in 2026, per the Medical Device and Diagnostic Industry.
VitalPatch is FDA-cleared. VitalConnect's platform can monitor up to 11 physiological parameters. VitalPatch leverages AI-enabled algorithms and transmits patient data directly through the cloud rather than requiring the device to be mailed back for analysis, allowing clinicians to access information without delay.
Betting on a $1 Billion Telemetry Market
Industry analysts say the acquisition unlocks access to a $1 billion mobile cardiac telemetry market that iRhythm's core Zio patch portfolio had previously only partially served, according to MedTech Dive. VitalConnect's sensors are built for live, multi-vital monitoring in hospitals and during the transition to home care — a combination iRhythm and VitalConnect say will give clinicians greater flexibility to choose an approach based on patient needs and care setting.
An estimated 27 million people in the United States are at risk for undiagnosed cardiac arrhythmias annually, highlighting the potential need for cardiac monitoring.
What the Deal Means for iRhythm's Finances
iRhythm expects the acquisition to boost its overall revenue growth rate starting in 2027 while preserving its existing target of a 15% adjusted EBITDA margin that same year, per Fierce Healthcare. The deal comes on the heels of strong standalone momentum: iRhythm reported $224.2 million in second-quarter 2026 revenue, a 20.1% year-over-year increase, and had raised its standalone full-year 2026 revenue guidance to between $875 million and $885 million before the acquisition closed.
iRhythm Holdings is headquartered in San Francisco.
Both companies frame the combination as a shared commitment to data quality and clinically actionable information, with VitalConnect and iRhythm saying the union is meant to create greater value for clinicians and patients alike. iRhythm is scheduled to report third-quarter earnings on November 5, 2026, when investors will get their first look at how the combined business is reflected in updated financial guidance.
